Claims for Patent: 12,433,891

Summary for Patent: 12,433,891

Title:	Amorphous solid dispersions of dasatinib and uses thereof
Abstract:	Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.
Inventor(s):	Christian F. Wertz, Tzehaw Chen
Assignee:	Handa Therapeutics LLC , Flex Pharma LLC
Application Number:	US17/737,409
Patent Claims:	1. A method of treating a patient with a leukemia, the method comprising: administering to the patient a pharmaceutical composition comprising an amorphous solid dispersion; wherein the amorphous solid dispersion comprises dasatinib and a methacrylic acid and ethyl acrylate copolymer that exhibits pH-dependent solubility; wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 30:70 to 95:5 (dasatinib:copolymer); and wherein the patient is co-administered a gastric acid-reducing agent selected from the group consisting of an H2 antagonist or a proton pump inhibitor. 2. The method of claim 1, wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater. 3. The method of claim 1, wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 40:60 to 70:30 (dasatinib:copolymer). 4. The method of claim 3, wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater. 5. The method of claim 1, wherein the pharmaceutical composition is a solid dosage form suitable for oral administration. 6. The method of claim 1, wherein the pharmaceutical composition is a gastric acid-insensitive composition. 7. A method of treating a patient with a leukemia, the method comprising: administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising an amorphous solid dispersion; wherein the amorphous solid dispersion comprises dasatinib and a methacrylic acid and ethyl acrylate copolymer that exhibits pH-dependent solubility; wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 30:70 to 95:5 (dasatinib:copolymer); and wherein the therapeutically effective amount comprises 20 mg to 140 mg dasatinib and wherein the patient has gastric pH greater than 5. 8. The method of claim 7, wherein the patient's gastric pH of greater than 5 is due to achlorhydria or hypochlorhydria. 9. The method of claim 7, wherein the patient's gastric pH of greater than 5 is due to a Helicobacter pylori infection. 10. The method of claim 7, wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater. 11. The method of claim 7, wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 40:60 to 70:30 (dasatinib:copolymer). 12. The method of claim 11, wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater. 13. The method of claim 7, wherein the pharmaceutical composition is a solid dosage form suitable for oral administration. 14. The method of claim 7, wherein the pharmaceutical composition is a gastric acid-insensitive composition. 15. A method of treating a patient with a leukemia, the method comprising administering to the patient a pharmaceutical composition comprising an amorphous solid dispersion; wherein the amorphous solid dispersion comprises dasatinib and a methacrylic acid and ethyl acrylate copolymer that exhibits pH-dependent solubility; wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 30:70 to 95:5 (dasatinib:copolymer); and wherein the pharmaceutical composition is administered without regard to whether the patient has elevated gastric pH. 16. The method of claim 15, wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater. 17. The method of claim 15, wherein the dasatinib and the copolymer are present in the amorphous solid dispersion in a w/w ratio of 40:60 to 70:30 (dasatinib:copolymer). 18. The method of claim 15, wherein the pharmaceutical composition is a solid dosage form suitable for oral administration. 19. The method of claim 15, wherein the pharmaceutical composition is a gastric acid-insensitive composition. 20. The method of claim 17, wherein the copolymer is insoluble in an aqueous medium at pH of 5 or lower, and soluble in an aqueous medium at pH 5.5 or greater.